GlassScriptPhysician profile
Sherief Kamel
NPI 1265474563
$44,868.18
in general payments reported to CMS, 2019-2025
52 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,228 · 2021: $4,459 · 2022: $5,176 · 2023: $5,959 · 2024: $1,047 · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,153.62 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $15,351.80 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,280.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $959.24 | 2021-2025 | Minimed 780g, Inceptiv, Inpen Smart Insulin Delivery System |
| Amgen INC. | $544.61 | 2019-2025 | Evenity, Repatha, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $481.22 | 2021-2025 | |
| Abbott Laboratories | $443.57 | 2021-2025 | Freestyle Libre, Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $387.88 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $371.52 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $344.57 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $340.92 | 2019-2023 | |
| Medtronic Minimed, INC. | $334.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $323.45 | 2019-2022 | |
| Horizon Therapeutics Plc | $256.26 | 2021-2023 | Tepezza |
| Abbvie INC. | $245.35 | 2020-2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherief Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.